Pharmacokinetics of intravenous polymyxin B in critically ill patients

Clinical Infectious Diseases

Volumn 47, Issue 10, 2008, Pages 1298-1304

  Zavascki, Alexandre P ^a,b   Goldani, Luciano Z ^a   Cao, Guoying ^c,d   Superti, Silvana V ^b   Lutz, Larissa ^a   Barth, Afonso L ^a   Ramos, Fabiano ^b   Boniatti, Márcio M ^a   Nation, Roger L ^c   Li, Jian ^c  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c MONASH UNIVERSITY   (Australia)

^d BEIJING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

POLYMYXIN B;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRITICAL ILLNESS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLASMA; POLYMYXIN B; PROTEIN BINDING; URINE;

EID: 54249107903     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/592577     Document Type: Article

References (32)

1. Infectious Diseases Society of America. Bad bugs, no drugs. 2004. Available at: http://www.idsociety.org/badbugsnodrugs.html. Accessed 3 October 2008.
2. Livermore DM. The need for new antibiotics. Clin Microbiol Infect 2004; 10(Suppl 4):1-9.
3. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42:657-68.
4. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6:589-601.
5. Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 2007; 60:1206-15.
6. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999; 33:960-7.
7. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40:1333-41.
8. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant gram-negative bacteria. Int J Antimicrob Agents 2005; 25:11-25.
9. Goodwin NJ. Colistin sulfate versus sodium colistimethate. Ann Intern Med 1969; 70:232-3.
10. Conway SP, Etherington C, Munday J, Goldman MH, Strong JJ, Wootton M. Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis. Ann Pharmacother 2000; 34:1238-42.
11. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36:1111-8.
12. Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 2005; 39:15-20.
13. Reed MD, Stern RC, O'Riordan MA, Blumer JL. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 2001; 41:645-54.
14. Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45:781-5.
15. Owen RJ, Li J, Nation RL, Spelman D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007; 59:473-7.
16. Tam VH, Schilling AN, Vo G, et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49:3624-30.
17. Li J, Coulthard K, Milne R, et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003; 52:987-92.
18. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 2003; 47:1766-70.
19. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004; 53:837-40.
20. Li J, Rayner CR, Nation RL, et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2005; 49:4814-5.
21. Le Brun PPH, de Boer AH, Mannes GPM, et al. Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 2: inhalation of a novel colistin dry powder formulation - a feasibility study in healthy volunteers and patients. Eur J Pharm Biopharm 2002; 54:25-32.
22. Kwa AL, Lim TP, Low JG, et al. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis 2008; 60:163-7.
23. Polymyxin B for injection [package insert]. Bedford, OH: Bedford Laboratories, 2007.
24. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54731 clinical isolates of gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect 2006; 12:315-21.
25. Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005; 165:1430-5.
26. Li J, Nation RL. Old polymyxins are back, is resistance close? Clin Infect Dis 2006; 43:663-4.
27. Nicolau DP, Quintiliani R, Nightingale CH. Antibiotic kinetics and dynamics for the clinician. Med Clin North Am 1995; 79:477-95.
28. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: 18th informational supplement. CLSI document M100-S18. Wayne, PA: CLSI, 2008.
29. Piafsky KM, Borga O. Plasma protein binding of basic drugs. II. Importance of α 1-acid glycoprotein for interindividual variation. Clin Pharmacol Ther 1977; 22:545-9.
30. Zamacona MK, Suarez E, Aguilera L, Rodriguez S, Aguirre C, Calvo R. Serum protein binding of propofol in critically ill patients. Acta Anaesthesiol Scand 1997; 41:1267-72.
31. De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 2002; 41:1135-51.
32. Hoeprich PD. The polymyxins. Med Clin North Am 1970; 54:1257-65.